Rapport Therapeutics, Inc.
RAPP
$27.62
-$0.22-0.79%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 8.25M | 7.71M | 6.82M | 7.54M | 6.32M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 38.51M | 29.99M | 29.50M | 27.11M | 23.52M |
| Operating Income | -38.51M | -29.99M | -29.50M | -27.11M | -23.52M |
| Income Before Tax | -33.76M | -26.93M | -26.73M | -24.06M | -19.98M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -33.76M | -26.93M | -26.73M | -24.06M | -19.98M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -33.76M | -26.93M | -26.73M | -24.06M | -19.98M |
| EBIT | -38.51M | -29.99M | -29.50M | -27.11M | -23.52M |
| EBITDA | -38.24M | -29.73M | -29.24M | -26.86M | -23.26M |
| EPS Basic | -0.72 | -0.71 | -0.75 | -0.68 | -0.57 |
| Normalized Basic EPS | -0.45 | -0.44 | -0.47 | -0.43 | -0.36 |
| EPS Diluted | -0.72 | -0.71 | -0.75 | -0.68 | -0.57 |
| Normalized Diluted EPS | -0.45 | -0.44 | -0.47 | -0.43 | -0.36 |
| Average Basic Shares Outstanding | 46.98M | 37.93M | 35.44M | 35.27M | 35.07M |
| Average Diluted Shares Outstanding | 46.98M | 37.93M | 35.44M | 35.27M | 35.07M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |